# US 2013/0251706 A1 · Combined use of fc gamma riib (cd32b) and cd20 - specific antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251706 A1
- Document ID: US20130251706A1
- Status: Published application
- Kind: A1
- Application number: 13/817,744
- Filed: 2011-08-19
- Published: 2013-09-26
- Earliest claimed: 2010-08-20
- Assignees: University of Southampton
- Inventors: Mark Cragg; Martin Glennie; Ali Roghanian; Stephen Beers; Peter Johnson; Sean Lim; Bjorn Frendeus; Ingrid Teige
- Web page: https://patentgrep.com/patent/US20130251706A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2887: {against CD20}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.

## Claims

### Claim 1

A composition comprising;
(i) an antibody molecule that specifically binds a cell surface antigen of a target cell, which antibody has a Fc domain capable of binding FcγRIIb; in combination with
(ii) an agent that prevents or reduces FcγRIIb binding to the Fc domain of the antibody molecule.

### Claim 2

(canceled)

### Claim 3

A method of treating a patient having target cells that express FcγRIIb, the method comprising selecting a patient having target cells that express an elevated level of FcγRIIb and administering to the patient (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcγRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcγRIIb.

### Claim 4

(canceled)

### Claim 5

A method for predicting the response of target cells of a patient to treatment with an antibody molecule that specifically binds a target cell surface antigen and has an Fc domain capable of binding FcγRIIb; characterized in that the method comprises determining the level of expression of FcγRIIb on the target cells, whereby elevated levels of FcγRIIb are predictive of a reduction in, or the absence of, a response to treatment with the antibody molecule.

### Claim at position 6

6-33. (canceled)

### Claim 34 (depends on 1)

The composition of claim 1, wherein the agent prevents or reduces FcγRIIb present on the target cell from binding to the Fc domain of the antibody molecule.

### Claim 35 (depends on 1)

The composition of claim 1, wherein the antibody molecule that specifically binds a cell surface antigen of a target cell has a Fc domain capable of binding FcγRIIb and is capable of being internalized into the target cell in an FcγRIIb-dependent manner.

### Claim 36 (depends on 1)

The composition of claim 1, wherein the agent that prevents or reduces FcγRIIb binding to the Fc domain of the antibody molecule additionally prevents or reduces internalization of the antibody molecule into the target cell.

### Claim 37 (depends on 1)

The composition of claim 1, wherein the target cell is a cancer cell, a B cell, or both.

### Claim 38 (depends on 1)

The composition of claim 1, wherein the cancer is non-Hodgkin lymphoma or chronic lymphocytic leukaemia.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the cancer is non-Hodgkin lymphoma selected from the group consisting of: follicular lymphoma, diffuse large B cell lymphoma, and mantle cell lymphoma.

### Claim 40 (depends on 1)

The composition of claim 1, wherein the agent is selected from the group consisting of: a polypeptide; an anticalin; a peptide; an antibody; a chimeric antibody; a single chain antibody; an aptamer; a darpin; a Fab, F(ab′)2, Fv, ScFv or dAb antibody fragment; a small molecule; a natural product; an affibody; a peptidomimetic; a nucleic acid; a peptide nucleic acid molecule; a lipid; a carbohydrate, an ankyrin repeat protein, an armadillo repeat protein, a leucine rich protein, a tetrariopeptide repeat protein, and a Designed Ankyrin Repeat Proteins (DARPins).

### Claim 41 (depends on 1)

The composition of claim 1, wherein the agent is one or more monoclonal antibody molecules that specifically bind FcγRIIb and do not include a domain capable of recruiting an effector cell.

### Claim 42 (depends on 1)

The composition of claim 1, wherein the agent comprises a variable heavy chain (VH) comprising the following CDRs:
(i) SEQ ID NO: 29 and SEQ ID NO: 30 and SEQ ID NO: 31; or
(ii) SEQ ID NO: 35 and SEQ ID NO: 36 and SEQ ID NO: 37; or
(iii) SEQ ID NO: 41 and SEQ ID NO: 42 and SEQ ID NO: 43; or
(iv) SEQ ID NO: 47 and SEQ ID NO: 48 and SEQ ID NO: 49; or
(v) SEQ ID NO: 53 and SEQ ID NO: 54 and SEQ ID NO: 55; or
(vi) SEQ ID NO: 59 and SEQ ID NO: 60 and SEQ ID NO: 61; or
(vii) SEQ ID NO: 65 and SEQ ID NO: 66 and SEQ ID NO: 67; or
(viii) SEQ ID NO: 71 and SEQ ID NO: 72 and SEQ ID NO: 73; or
(ix) SEQ ID NO: 77 and SEQ ID NO: 78 and SEQ ID NO: 79; or
(x) SEQ ID NO: 83 and SEQ ID NO: 84 and SEQ ID NO: 85; or
(xi) SEQ ID NO: 89 and SEQ ID NO: 90 and SEQ ID NO: 91; or
(xii) SEQ ID NO: 95 and SEQ ID NO: 96 and SEQ ID NO: 97; or
(xiii) SEQ ID NO: 101 and SEQ ID NO: 102 and SEQ ID NO: 103.

### Claim 43 (depends on 1)

The composition of claim 1, wherein the agent comprises a variable light chain (VL) comprising the following CDRs:
(i) SEQ ID NO: 32 and SEQ ID NO: 33 and SEQ ID NO: 34; or
(ii) SEQ ID NO: 38 and SEQ ID NO: 39 and SEQ ID NO: 40; or
(iii) SEQ ID NO: 44 and SEQ ID NO: 45 and SEQ ID NO: 46; or
(iv) SEQ ID NO: 50 and SEQ ID NO: 51 and SEQ ID NO: 52; or
(v) SEQ ID NO: 56 and SEQ ID NO: 57 and SEQ ID NO: 58; or
(vi) SEQ ID NO: 62 and SEQ ID NO: 63 and SEQ ID NO: 64; or
(vii) SEQ ID NO: 68 and SEQ ID NO: 69 and SEQ ID NO: 70; or
(viii) SEQ ID NO: 74 and SEQ ID NO: 75 and SEQ ID NO: 76; or
(ix) SEQ ID NO: 80 and SEQ ID NO: 81 and SEQ ID NO: 82; or
(x) SEQ ID NO: 86 and SEQ ID NO: 87 and SEQ ID NO: 88; or
(xi) SEQ ID NO: 92 and SEQ ID NO: 93 and SEQ ID NO: 94; or
(xii) SEQ ID NO: 98 and SEQ ID NO: 99 and SEQ ID NO: 100; or
(xiii) SEQ ID NO: 104 and SEQ ID NO: 105 and SEQ ID NO: 106.

### Claim 44 (depends on 1)

The composition of claim 1, wherein the agent comprises a variable heavy chain (VH) amino acid sequence selected from the group consisting of: SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5, SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; and SEQ ID NO: 15; and/or a variable light chain (VL) amino acid sequence selected from the group consisting of: SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO:23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; and SEQ ID NO: 28.

### Claim 45 (depends on 1)

The composition of claim 1, wherein the agent comprises the following CDR amino acid sequences:
(i) SEQ ID NO: 29 and SEQ ID NO: 30 and SEQ ID NO: 31 and SEQ ID NO: 32 and SEQ ID NO: 33 and SEQ ID NO: 34; or
(ii) SEQ ID NO: 35 and SEQ ID NO: 36 and SEQ ID NO: 37 and SEQ ID NO: 38 and SEQ ID NO: 39 and SEQ ID NO: 40; or
(iii) SEQ ID NO: 41 and SEQ ID NO: 42 and SEQ ID NO: 43 and SEQ ID NO: 44 and SEQ ID NO: 45 and SEQ ID NO: 46; or
(iv) SEQ ID NO: 47 and SEQ ID NO: 48 and SEQ ID NO: 49 and SEQ ID NO: 50 and SEQ ID NO: 51 and SEQ ID NO: 52; or
(v) SEQ ID NO: 53 and SEQ ID NO: 54 and SEQ ID NO: 55 and SEQ ID NO: 56 and SEQ ID NO: 57 and SEQ ID NO: 58; or
(vi) SEQ ID NO: 59 and SEQ ID NO: 60 and SEQ ID NO: 61 and SEQ ID NO: 62 and SEQ ID NO: 63 and SEQ ID NO: 64; or
(vii) SEQ ID NO: 65 and SEQ ID NO: 66 and SEQ ID NO: 67 and SEQ ID NO: 68 and SEQ ID NO: 69 and SEQ ID NO: 70; or
(viii) SEQ ID NO: 71 and SEQ ID NO: 72 and SEQ ID NO: 73 and SEQ ID NO: 74 and SEQ ID NO: 75 and SEQ ID NO: 76; or
(ix) SEQ ID NO: 77 and SEQ ID NO: 78 and SEQ ID NO: 79 and SEQ ID NO: 80 and SEQ ID NO: 81 and SEQ ID NO: 82; or
(x) SEQ ID NO: 83 and SEQ ID NO: 84 and SEQ ID NO: 85 and SEQ ID NO: 86 and SEQ ID NO: 87 and SEQ ID NO: 88; or
(xi) SEQ ID NO: 89 and SEQ ID NO: 90 and SEQ ID NO: 91 and SEQ ID NO: 92 and SEQ ID NO: 93 and SEQ ID NO: 94; or
(xii) SEQ ID NO: 95 and SEQ ID NO: 96 and SEQ ID NO: 97 and SEQ ID NO: 98 and SEQ ID NO: 99 and SEQ ID NO: 100; or
(xiii) SEQ ID NO: 101 and SEQ ID NO: 102 and SEQ ID NO: 103 and SEQ ID NO: 104 and SEQ ID NO: 105 and SEQ ID NO: 106.

### Claim 46 (depends on 1)

The composition of claim 1, wherein the agent comprises the following amino acid sequences:
(i) SEQ ID NO: 3 and SEQ ID NO: 16; or
(ii) SEQ IS NO: 4 and SEQ ID NO: 17; or
(iii) SEQ IS NO: 5 and SEQ ID NO: 18; or
(iv) SEQ ID NO: 6 and SEQ ID NO: 19; or
(v) SEQ ID NO: 7 and SEQ ID NO: 20; or
(vi) SEQ ID NO: 8 and SEQ ID NO: 21; or
(vii) SEQ ID NO: 9 and SEQ ID NO: 22; or
(viii) SEQ ID NO: 10 and SEQ ID NO: 23; or
(ix) SEQ ID NO: 11 and SEQ ID NO: 24; or
(x) SEQ ID NO: 12 and SEQ ID NO: 25; or
(xi) SEQ ID NO: 13 and SEQ ID NO: 26; or
(xii) SEQ ID NO: 14 and SEQ ID NO: 27; or
(xiii) SEQ ID NO: 15 and SEQ ID NO: 28.

### Claim 47 (depends on 1)

The composition of claim 1, wherein the agent prevents or reduces FcγRIIb signaling, prevents or reduces internalization of the antibody molecule by the target cell, or both.

### Claim 48 (depends on 1)

The composition of claim 1, wherein the cell surface antigen is selected from CD19, CD20 or CD40.

### Claim 49 (depends on 1)

The composition of claim 1, wherein the antibody molecule specifically binding to a cell surface antigen is a CD20 antibody.

### Claim 50 (depends on 49)

The composition of claim 49, wherein the cell surface antigen is CD20 and the antibody molecule specifically binding to a cell surface antigen is a Type I CD20 antibody.

### Claim 51 (depends on 1)

A method of treating a patient having target cells that express FcγRIIb, the method comprising selecting a patient having target cells that express an elevated level of FcγRIIb and administering to the patient, the composition of claim 1.

### Claim 52 (depends on 51)

The method of claim 51, wherein elevated FcγRIIb expression on the target cells is determined relative to a control, and preferably the control is the normal level of FcγRIIb expression in cells of the same type as the target cells.

### Claim 53 (depends on 51)

The method of claim 51, wherein the patient to be treated is a cancer patient and the treatment is a cancer treatment.

### Claim 54 (depends on 51)

The method of claim 51, wherein the agent prevents or reduces FcγRIIb present on the target cell from binding to the Fc domain of the antibody molecule.

### Claim 55 (depends on 51)

The method of claim 51, wherein the antibody molecule that specifically binds a cell surface antigen of a target cell has a Fc domain capable of binding FcγRIIb and is capable of being internalized into the target cell in an FcγRIIb-dependent manner.

### Claim 56 (depends on 51)

The method of claim 51, wherein the agent that prevents or reduces FcγRIIb binding to the Fc domain of the antibody molecule additionally prevents or reduces internalization of the antibody molecule into the target cell.

### Claim 57 (depends on 51)

The method of claim 51, wherein the target cell is a cancer cell, a B cell, or both.

### Claim 58 (depends on 51)

The method of claim 51, wherein the cancer is non-Hodgkin lymphoma or chronic lymphocytic leukaemia.

### Claim 59 (depends on 58)

The method of claim 58, wherein the cancer is non-Hodgkin lymphoma selected from the group consisting of: follicular lymphoma, diffuse large B cell lymphoma, and mantle cell lymphoma.

### Claim 60 (depends on 51)

The method of claim 51, wherein the agent is selected from the group consisting of: a polypeptide; an anticalin; a peptide; an antibody; a chimeric antibody; a single chain antibody; an aptamer; a darpin; a Fab, F(ab′)2, Fv, ScFv or dAb antibody fragment; a small molecule; a natural product; an affibody; a peptidomimetic; a nucleic acid; a peptide nucleic acid molecule; a lipid; a carbohydrate, an ankyrin repeat protein, an armadillo repeat protein, a leucine rich protein, a tetrariopeptide repeat protein, and a Designed Ankyrin Repeat Proteins (DARPins).

### Claim 61 (depends on 51)

The method of claim 51, wherein the agent is one or more monoclonal antibody molecules that specifically bind FcγRIIb and do not include a domain capable of recruiting an effector cell.

### Claim 62 (depends on 51)

The method of claim 51, wherein the agent comprises a variable heavy chain (VH) comprising the following CDRs:
(i) SEQ ID NO: 29 and SEQ ID NO: 30 and SEQ ID NO: 31; or
(ii) SEQ ID NO: 35 and SEQ ID NO: 36 and SEQ ID NO: 37; or
(iii) SEQ ID NO: 41 and SEQ ID NO: 42 and SEQ ID NO: 43; or
(iv) SEQ ID NO: 47 and SEQ ID NO: 48 and SEQ ID NO: 49; or
(v) SEQ ID NO: 53 and SEQ ID NO: 54 and SEQ ID NO: 55; or
(vi) SEQ ID NO: 59 and SEQ ID NO: 60 and SEQ ID NO: 61; or
(vii) SEQ ID NO: 65 and SEQ ID NO: 66 and SEQ ID NO: 67; or
(viii) SEQ ID NO: 71 and SEQ ID NO: 72 and SEQ ID NO: 73; or
(ix) SEQ ID NO: 77 and SEQ ID NO: 78 and SEQ ID NO: 79; or
(x) SEQ ID NO: 83 and SEQ ID NO: 84 and SEQ ID NO: 85; or
(xi) SEQ ID NO: 89 and SEQ ID NO: 90 and SEQ ID NO: 91; or
(xii) SEQ ID NO: 95 and SEQ ID NO: 96 and SEQ ID NO: 97; or
(xiii) SEQ ID NO: 101 and SEQ ID NO: 102 and SEQ ID NO: 103.

### Claim 63 (depends on 51)

The method of claim 51, wherein the agent comprises a variable light chain (VL) comprising the following CDRs:
(i) SEQ ID NO: 32 and SEQ ID NO: 33 and SEQ ID NO: 34; or
(ii) SEQ ID NO: 38 and SEQ ID NO: 39 and SEQ ID NO: 40; or
(iii) SEQ ID NO: 44 and SEQ ID NO: 45 and SEQ ID NO: 46; or
(iv) SEQ ID NO: 50 and SEQ ID NO: 51 and SEQ ID NO: 52; or
(v) SEQ ID NO: 56 and SEQ ID NO: 57 and SEQ ID NO: 58; or
(vi) SEQ ID NO: 62 and SEQ ID NO: 63 and SEQ ID NO: 64; or
(vii) SEQ ID NO: 68 and SEQ ID NO: 69 and SEQ ID NO: 70; or
(viii) SEQ ID NO: 74 and SEQ ID NO: 75 and SEQ ID NO: 76; or
(ix) SEQ ID NO: 80 and SEQ ID NO: 81 and SEQ ID NO: 82; or
(x) SEQ ID NO: 86 and SEQ ID NO: 87 and SEQ ID NO: 88; or
(xi) SEQ ID NO: 92 and SEQ ID NO: 93 and SEQ ID NO: 94; or
(xii) SEQ ID NO: 98 and SEQ ID NO: 99 and SEQ ID NO: 100; or
(xiii) SEQ ID NO: 104 and SEQ ID NO: 105 and SEQ ID NO: 106.

### Claim 64 (depends on 51)

The method of claim 51, wherein the agent comprises a variable heavy chain (VH) amino acid sequence selected from the group consisting of: SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5, SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; and SEQ ID NO: 15; and/or a variable light chain (VL) amino acid sequence selected from the group consisting of: SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO:23; SEQ ID NO: 24; SEQ ID NO: 25; SEQ ID NO: 26; SEQ ID NO: 27; and SEQ ID NO: 28.

### Claim 65 (depends on 51)

The method of claim 51, wherein the agent comprises the following CDR amino acid sequences:
(i) SEQ ID NO: 29 and SEQ ID NO: 30 and SEQ ID NO: 31 and SEQ ID NO: 32 and SEQ ID NO: 33 and SEQ ID NO: 34; or
(ii) SEQ ID NO: 35 and SEQ ID NO: 36 and SEQ ID NO: 37 and SEQ ID NO: 38 and SEQ ID NO: 39 and SEQ ID NO: 40; or
(iii) SEQ ID NO: 41 and SEQ ID NO: 42 and SEQ ID NO: 43 and SEQ ID NO: 44 and SEQ ID NO: 45 and SEQ ID NO: 46; or
(iv) SEQ ID NO: 47 and SEQ ID NO: 48 and SEQ ID NO: 49 and SEQ ID NO: 50 and SEQ ID NO: 51 and SEQ ID NO: 52; or
(v) SEQ ID NO: 53 and SEQ ID NO: 54 and SEQ ID NO: 55 and SEQ ID NO: 56 and SEQ ID NO: 57 and SEQ ID NO: 58; or
(vi) SEQ ID NO: 59 and SEQ ID NO: 60 and SEQ ID NO: 61 and SEQ ID NO: 62 and SEQ ID NO: 63 and SEQ ID NO: 64; or
(vii) SEQ ID NO: 65 and SEQ ID NO: 66 and SEQ ID NO: 67 and SEQ ID NO: 68 and SEQ ID NO: 69 and SEQ ID NO: 70; or
(viii) SEQ ID NO: 71 and SEQ ID NO: 72 and SEQ ID NO: 73 and SEQ ID NO: 74 and SEQ ID NO: 75 and SEQ ID NO: 76; or
(ix) SEQ ID NO: 77 and SEQ ID NO: 78 and SEQ ID NO: 79 and SEQ ID NO: 80 and SEQ ID NO: 81 and SEQ ID NO: 82; or
(x) SEQ ID NO: 83 and SEQ ID NO: 84 and SEQ ID NO: 85 and SEQ ID NO: 86 and SEQ ID NO: 87 and SEQ ID NO: 88; or
(xi) SEQ ID NO: 89 and SEQ ID NO: 90 and SEQ ID NO: 91 and SEQ ID NO: 92 and SEQ ID NO: 93 and SEQ ID NO: 94; or
(xii) SEQ ID NO: 95 and SEQ ID NO: 96 and SEQ ID NO: 97 and SEQ ID NO: 98 and SEQ ID NO: 99 and SEQ ID NO: 100; or
(xiii) SEQ ID NO: 101 and SEQ ID NO: 102 and SEQ ID NO: 103 and SEQ ID NO: 104 and SEQ ID NO: 105 and SEQ ID NO: 106.

### Claim 66 (depends on 51)

The method of claim 51, wherein the agent comprises the following amino acid sequences:
(i) SEQ ID NO: 3 and SEQ ID NO: 16; or
(ii) SEQ IS NO: 4 and SEQ ID NO: 17; or
(iii) SEQ IS NO: 5 and SEQ ID NO: 18; or
(iv) SEQ ID NO: 6 and SEQ ID NO: 19; or
(v) SEQ ID NO: 7 and SEQ ID NO: 20; or
(vi) SEQ ID NO: 8 and SEQ ID NO: 21; or
(vii) SEQ ID NO: 9 and SEQ ID NO: 22; or
(viii) SEQ ID NO: 10 and SEQ ID NO: 23; or
(ix) SEQ ID NO: 11 and SEQ ID NO: 24; or
(x) SEQ ID NO: 12 and SEQ ID NO: 25; or
(xi) SEQ ID NO: 13 and SEQ ID NO: 26; or
(xii) SEQ ID NO: 14 and SEQ ID NO: 27; or
(xiii) SEQ ID NO: 15 and SEQ ID NO: 28.

### Claim 67 (depends on 51)

The method of claim 51, wherein the agent prevents or reduces FcγRIIb signaling, prevents or reduces internalization of the antibody molecule by the target cell, or both.

### Claim 68 (depends on 51)

The method of claim 51, wherein the cell surface antigen is selected from CD19, CD20 or CD40.

### Claim 69 (depends on 51)

The method of claim 51, wherein the antibody molecule specifically binding to a cell surface antigen is a CD20 antibody.

### Claim 70 (depends on 69)

The method of claim 69, wherein the cell surface antigen is CD20 and the antibody molecule specifically binding to a cell surface antigen is a Type I CD20 antibody.
